Novartis/Boehringer-Ingelheim Serentil
Executive Summary
Boxed warning about potential QTc prolongation associated with antipsychotic mesoridazine is added to labeling, and product is restricted to second-line status. The change is similar to a July relabeling for Novartis' chemically-related product Mellaril (1"The Pink Sheet" July 17, p. 12). Mesoridazine is a Mellaril (thioridazine) metabolite
You may also be interested in...
Novartis Mellaril Shifted To Second-Line Anti-Psychotic With QTc Black Box
Novartis Mellaril's black box warning that thioridazine causes QTc prolongation will shift it to a second-line anti-psychotic therapy.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials